Latest News
-
1:10 Split, Rs 299/Sh Dividend: Tata's Steel Stock Up 11% In 30-Days, Better Than Nifty; PL Says Accumulate -
625% Dividend, 1:10 Split, 3 Bonus; FMCG ITC Makes Big Acquisition Announcement; Stock Target Prices In April -
2:1 Bonus Issue: IT Penny Stock Turned; 1,600 Shares Market Lot Size Revised To 4,800 Shares -
FREE, FREE, FREE! 3:1 Bonus: Pharma Stock Hits Back-To-Back Upper Circuits; 500 Shares To Earn Rs 1,69,500 -
1:10 Stock Split: Below Rs 10, Fertilizer Sector Turned Ex-Split; 8,282% Returns In 5 Years -
Rs 17/Share Dividend: Record Date On April 26; Buy The ICICI Group Stock To Be Eligible? -
Honasa Consumer to Strengthen Operations by Merging Fusion Cosmeceutics and Just4Kids -
Wipro Reports 7.8% Decline in Q4 Net Profit; CEO Highlights Economic Challenges -
IREDA Hits Record Annual PAT of Rs 1,252 Cr in FY24; Q4 Profits Up by 33% -
Massive Employee Exodus Hits India's Top IT Companies in FY23-24
3 Board Meetings For Amalgamation, Bonus & Split, Quarterly Results & 3rd Interim Dividend
Board meetings are crucial from the perspective of both investors' as well as companies. For the listed companies it is both a mandate as well as indicator of the continuing performance at the firm, while for the investors' it helps them take a decision on their investments and typically such an action is far more important for short to medium term investors than long term investors.
1. Fermenta Bio:
The pharmaceuticals company on October 4, 2021 via an exchange filing intimated about the board meeting to be held on October 11. In the filing the company said that the Board of Directors of the Company will meet to consider and approve the Composite Scheme of Amalgamation and Arrangement amongst DVK Investments Private Limited (Transferor Company 1) and Aegean Properties Limited (Transferor Company 2) and Fermenta Biotech Limited (Transferee Company).
Earlier called as DIL Ltd., the company has a broad based exposure into various arenas including biotech, pharma, environmental solutions and real estate. The company is into manufacturing and marketing pharma ingredients as well as biotech products, including cholecalciferol, immobilized enzyme catalysts, candida antarctica lipase B, phenyramidol hydrochloride, and bio-enzymes
The scrip's last closing price is Rs. 309.10 per share on the NSE and commands a market-cap of Rs. 909 crore.
2. NCL Research:
The finance-investments sector company will meet on October 11 for considering stock split and bonus issue. On 5th October, the company via a BSE filing said that its board of directors will hold a meeting on October 11 for the following purposes:
a) Sub-Division of face value of Equity Shares and
b) Issue of Bonus Equity Shares
c) Change in Memorandum of Association for give effect of the agenda as stated above
d) Seek approval of the members of the Company for the above referred items as recommended by the Board.
Incorporated on 04 Feb.1985 as N.C.L. RESEARCH & FINANCIAL SERVICES LTD., the company is engaged in the activities of trading of Textiles products apart from investing activities in Shares and Securities.
3. HCL Technologies:
The IT major's board meet is scheduled for October 14, 2021 for its 2nd quarterly results and mulling over third interim dividend for the financial year 2022. The company as its previous two interim dividends announced a pay-out of Rs. 6 each.
The ex-date of the to be announced interim dividend has been already revealed as October 21, 2021. Investors are expecting a great deal from IT companies, whose shares have been on a roll over the last few quarters. It would be interesting to see if HCL Tech delivers or not.
Disclaimer
The above listed board meetings are for informational purpose as these are crucial for investors. Please note investing in stocks is subject to market risks and one needs to be cautious at this point of time as markets have gone-up sharply. So, this story in no way should be taken as a recommendation to buy in the above scrips. Neither the author, nor Greynium Information technologies Pvt Ltd would be responsible for losses incurred based on a decision made from this article.
